Kwality PharmaceuticalsBOM:539997 -3.48%64 Net Margin % is 16.10% as of Mar. 2026, which is 135% above its 10-year median of 6.85. GuruFocus rates BOM:539997 with a GF Score™ of 64/100 and a GF Value™ of ₹1,155.94 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 954 Drug Manufacturers companies, Kwality Pharmaceuticals ranks better than 74.32% on this metric.
The historical rank and industry rank for Kwality Pharmaceuticals's Net Margin % or its related term are showing as below:
BOM:539997'
s Net Margin % Range Over the Past 10 Years
Min: 3.31 Med: 6.85 Max: 26.3
Current: 13.39
BOM:539997's Net Margin % is ranked better than 74.32% of 954
companies
in the Drug Manufacturers industry
Industry Median: 5.695
vs BOM:539997: 13.39
Kwality Pharmaceuticals (BOM:539997) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Kwality Pharmaceuticals Net Margin % Related Terms
Kwality Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kwality Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kwality Pharmaceuticals Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kwality Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Kwality Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kwality Pharmaceuticals (BOM:539997) has a Net Margin % of 16.10% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Kwality Pharmaceuticals and its competitors. This is 135% above median its historical median of 6.85. Over the past decade, Kwality Pharmaceuticals' Net Margin % has ranged from 3.31 to 26.30. According to the industry distribution chart, Kwality Pharmaceuticals ranks #245 out of 954 companies in the Drug Manufacturers industry, placing it in the top 25.7%.
Is Kwality Pharmaceuticals' Net Margin % too high?
Kwality Pharmaceuticals' current Net Margin % of 16.10% is 135% above median its 10-year median of 6.85. Over the past 10 years, this metric has ranged from a low of 3.31 to a high of 26.30. The Drug Manufacturers industry median Net Margin % is 5.70. Kwality Pharmaceuticals' value of 16.10% is 182.7% above this industry median. Based on the distribution chart, Kwality Pharmaceuticals ranks #245 out of 954 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kwality Pharmaceuticals has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kwality Pharmaceuticals' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kwality Pharmaceuticals ranks #245 out of 954 companies for Net Margin %. This puts Kwality Pharmaceuticals in the upper half of its industry. The industry median Net Margin % is 5.70. Kwality Pharmaceuticals' value of 16.10% is 182.7% above this benchmark. Historically, Kwality Pharmaceuticals' own Net Margin % has ranged from 3.31 to 26.30 over the past decade. While the company's 10-year median is 6.85 vs. the industry median of 5.70, Kwality Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.70, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kwality Pharmaceuticals's current Net Margin % of 16.10% is 182.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Kwality Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kwality Pharmaceuticals's current Net Margin % is 16.10%, which is 135% above median its own 10-year median of 6.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kwality Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Kwality Pharmaceuticals (BOM:539997) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,155.94, compared to a current price of ₹2,704.70 — trading 134% above its estimated fair value. The current Net Margin % is 16.10%, which is 135% above median its 10-year median of 6.85 and 182.7% above the Drug Manufacturers industry median of 5.70. Kwality Pharmaceuticals' overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Kwality Pharmaceuticals (BOM:539997), the current Net Margin % is 16.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kwality Pharmaceuticals (BOM:539997) Overvalued in 2026?
Based on GuruFocus' analysis, Kwality Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹2,704.70 is trading 134% above its estimated GF Value™ of ₹1,155.94.
GuruFocus considers Kwality Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:539997:
Net Margin %: 16.10% (135% above median its 10-year median of 6.85)
GF Value™: ₹1,155.94 vs. price of ₹2,704.70 (134% above fair value)
Industry Position: 182.7% above the Drug Manufacturers median (#245 of 954)
No single metric tells the full story. See the BOM:539997 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kwality Pharmaceuticals Ltd is an India-based pharmaceutical company. It is principally engaged in manufacturing finished pharmaceutical formulations in a dosage form. The company manufactures and exports pharmaceutical formulations in liquid orals, dry syrups, tablets, capsules, sterile powder for injections, and small-volume injectables.
64GF Score
Get the complete analysis for BOM:539997
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539997 has been successfully added to your 
